MedPath

Idorsia Ltd

Idorsia Ltd logo
🇨🇭Switzerland
Ownership
Subsidiary
Employees
-
Market Cap
$464M
Website
http://www.idorsia.com

A Study to Evaluate ID-085 in People With Mild, Moderate, and Severe Kidney Disease

Phase 1
Completed
Conditions
Renal Impairment
Interventions
First Posted Date
2019-04-12
Last Posted Date
2019-11-22
Lead Sponsor
Idorsia Pharmaceuticals Ltd.
Target Recruit Count
32
Registration Number
NCT03913000
Locations
🇩🇪

CRS Clinical Research Services Kiel GmbH, Kiel, Germany

A Clinical Study to Examine the Drug-drug Interactions Between ACT-541468 and Citalopram in Healthy Male and Female Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: ACT541468 placebo
First Posted Date
2019-04-08
Last Posted Date
2019-10-31
Lead Sponsor
Idorsia Pharmaceuticals Ltd.
Target Recruit Count
24
Registration Number
NCT03907215
Locations
🇩🇪

Parexel International GmbH, Berlin, Germany

A Clinical Study to Assess Next-day Driving Performance Following Administration of ACT-541468 in Middle-aged and Elderly Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2019-03-27
Last Posted Date
2019-10-31
Lead Sponsor
Idorsia Pharmaceuticals Ltd.
Target Recruit Count
56
Registration Number
NCT03892902
Locations
🇳🇱

Centre for Human Drug Research, Leiden, Netherlands

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of ACT-1004-1239 in Healthy Male Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
Other: Placebo (Food-effect subpart)
Other: Placebo
Drug: ACT-1004-1239 (Food-effect subpart)
First Posted Date
2019-03-11
Last Posted Date
2020-01-10
Lead Sponsor
Idorsia Pharmaceuticals Ltd.
Target Recruit Count
64
Registration Number
NCT03869320
Locations
🇺🇸

Pharmaron CPC, Inc. & Affiliates, Baltimore, Maryland, United States

A Study in Healthy Subjects to Investigate Whether Administration of Lucerastat Can Affect Normal Heart Function

First Posted Date
2019-02-06
Last Posted Date
2019-10-31
Lead Sponsor
Idorsia Pharmaceuticals Ltd.
Target Recruit Count
44
Registration Number
NCT03832452
Locations
🇳🇱

QPS Netherlands B.V., Groningen, Netherlands

A Study to Investigate the Effect of Rifampicin on the Uptake and Breakdown of ACT-246475 in Healthy Subjects

Phase 1
Completed
Conditions
Healthy Subject
Interventions
First Posted Date
2019-01-23
Last Posted Date
2022-11-16
Lead Sponsor
Idorsia Pharmaceuticals Ltd.
Target Recruit Count
14
Registration Number
NCT03814200
Locations
🇳🇱

QPS Netherlands B.V., Groningen, Netherlands

A Clinical Study to Investigate the Food Effect on the Pharmacokinetics of ACT-541468 in Healthy Male Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2019-01-10
Last Posted Date
2019-04-12
Lead Sponsor
Idorsia Pharmaceuticals Ltd.
Target Recruit Count
20
Registration Number
NCT03799978
Locations
🇨🇿

CEPHA s.r.o., Pilsen, Czechia

A Study to Investigate the Effects of ACT-541468 on Nighttime Respiratory Function in Patients With Mild to Moderate Obstructive Sleep Apnea

Phase 1
Completed
Conditions
Obstructive Sleep Apnea
Interventions
Drug: Placebo
First Posted Date
2018-12-05
Last Posted Date
2019-12-19
Lead Sponsor
Idorsia Pharmaceuticals Ltd.
Target Recruit Count
28
Registration Number
NCT03765294
Locations
🇩🇪

Advanced Sleep Research, Berlin, Germany

Efficacy and Safety of Four Doses of Cenerimod Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus

Phase 2
Completed
Conditions
Systemic Lupus Erythematosus
Interventions
First Posted Date
2018-11-15
Last Posted Date
2023-09-22
Lead Sponsor
Idorsia Pharmaceuticals Ltd.
Target Recruit Count
427
Registration Number
NCT03742037
Locations
🇺🇸

North Georgia Rheumatology Group - Duluth, Lawrenceville, Georgia, United States

🇺🇸

Pinnacle Research Group, Anniston, Alabama, United States

🇫🇷

Hôpital Haut-Lévêque, Pessac, France

and more 145 locations

A Study to Evaluate the Long-term Safety and Tolerability of Lucerastat in Adult Subjects With Fabry Disease

Phase 3
Active, not recruiting
Conditions
Fabry Disease
Interventions
First Posted Date
2018-11-09
Last Posted Date
2024-07-03
Lead Sponsor
Idorsia Pharmaceuticals Ltd.
Target Recruit Count
107
Registration Number
NCT03737214
Locations
🇺🇸

University of Utah - Division of Medical Genetics, Clinical Genetics Research, Salt Lake City, Utah, United States

🇺🇸

University of California Irvine, Irvine, California, United States

🇺🇸

University of Pennsylvania - Dept of Medicine, Philadelphia, Pennsylvania, United States

and more 39 locations
© Copyright 2025. All Rights Reserved by MedPath